Figure 4.
The CD200R-CD28 switch receptor potently enhances the in vivo efficacy of BCMA- and TnMUC1-specific CAR T cells. (A) RPMI-CD200-CBG extramedullary (flank) plasmacytoma model was performed for BCMA CAR T cells. NSG mice received implantation with RPMI-CD200-CBG tumor cells on the right flank on day 0. The mice were treated with indicated BCMA CAR T cells (IV) at day 14 after tumor inoculation. At indicated time points, flank tumors were measured by calipers (left), and animals were imaged (middle left). The percentage survival per group was determined on a daily basis and is represented in a Kaplan-Meier survival curve (middle right). Two weeks after T-cell treatment, Trucount assays (BD Biosciences) were performed for the T cells in the blood. (B) RPMI-CD200-CBG extramedullary plasmacytoma model was performed for TnMUC1 CAR T cells. (C) NSG mice received implantation with MM.1S-CD200-CBG tumor cells via the tail vein on day 0. The mice were treated with indicated BCMA CAR T cells (IV) at day 21 after tumor inoculation. At indicated time points, animals were imaged (left) and body-weight change was recorded (right). The percentage survival per group was determined on a daily basis and is represented in a Kaplan-Meier survival curve (middle). (D) Flow cytometry analysis of memory T-cell phenotype population in the blood after 2 weeks of T-cell treatment. (E) Flow cytometry counting for T cells resident in the spleen at 3 weeks of T-cell treatment. Data are shown as mean ± SD, ∗P < .05, ∗∗P < .01, ∗∗∗P < .001, and ∗∗∗∗P < .0001; differences in survival are determined by log-rank sum test (panels A-C); differences in tumor growth are determined by 2-way ANOVA and Tukey multiple comparison test; differences in the blood (panels A-B) and the spleen (panel E) T-cell number are determined by 1-way ANOVA and Tukey multiple comparison test.

The CD200R-CD28 switch receptor potently enhances the in vivo efficacy of BCMA- and TnMUC1-specific CAR T cells. (A) RPMI-CD200-CBG extramedullary (flank) plasmacytoma model was performed for BCMA CAR T cells. NSG mice received implantation with RPMI-CD200-CBG tumor cells on the right flank on day 0. The mice were treated with indicated BCMA CAR T cells (IV) at day 14 after tumor inoculation. At indicated time points, flank tumors were measured by calipers (left), and animals were imaged (middle left). The percentage survival per group was determined on a daily basis and is represented in a Kaplan-Meier survival curve (middle right). Two weeks after T-cell treatment, Trucount assays (BD Biosciences) were performed for the T cells in the blood. (B) RPMI-CD200-CBG extramedullary plasmacytoma model was performed for TnMUC1 CAR T cells. (C) NSG mice received implantation with MM.1S-CD200-CBG tumor cells via the tail vein on day 0. The mice were treated with indicated BCMA CAR T cells (IV) at day 21 after tumor inoculation. At indicated time points, animals were imaged (left) and body-weight change was recorded (right). The percentage survival per group was determined on a daily basis and is represented in a Kaplan-Meier survival curve (middle). (D) Flow cytometry analysis of memory T-cell phenotype population in the blood after 2 weeks of T-cell treatment. (E) Flow cytometry counting for T cells resident in the spleen at 3 weeks of T-cell treatment. Data are shown as mean ± SD, ∗P < .05, ∗∗P < .01, ∗∗∗P < .001, and ∗∗∗∗P < .0001; differences in survival are determined by log-rank sum test (panels A-C); differences in tumor growth are determined by 2-way ANOVA and Tukey multiple comparison test; differences in the blood (panels A-B) and the spleen (panel E) T-cell number are determined by 1-way ANOVA and Tukey multiple comparison test.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal